{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:21:31Z","timestamp":1787739691311,"version":"build-2784847793"},"reference-count":58,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013220","name":"Ultragenyx Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013220","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ymgme.2024.108145","type":"journal-article","created":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T16:52:32Z","timestamp":1705510352000},"page":"108145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Mucopolysaccharidosis type VII (Sly syndrome) - What do we know?"],"prefix":"10.1016","volume":"141","author":[{"given":"Christina L.","family":"Grant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"L\u00f3pez-Valdez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Marsden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatih","family":"Ezg\u00fc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ymgme.2024.108145_bb0005","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0022-3476(73)80162-3","article-title":"Beta glucuronidase deficiency: report of clinical, radiologic, and biochemical features of a new mucopolysaccharidosis","volume":"82","author":"Sly","year":"1973","journal-title":"J. Pediatr."},{"issue":"7","key":"10.1016\/j.ymgme.2024.108145_bb0010","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.3390\/ijms21072515","article-title":"Parenti G, Pathogenesis of mucopolysaccharidoses, an update","volume":"21","author":"Fecarotta","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108145_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5582\/irdr.2020.01011","article-title":"A basic understanding of mucopolysaccharidosis: incidence, clinical features, diagnosis, and management","volume":"9","author":"Zhou","year":"2020","journal-title":"Intractable Rare Dis. Res."},{"issue":"3","key":"10.1016\/j.ymgme.2024.108145_bb0020","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00256-013-1797-y","article-title":"Mucopolysaccharidosis IVA (Morquio a syndrome) and VI (Maroteaux-Lamy syndrome): under-recognized and challenging to diagnose","volume":"43","author":"Lachman","year":"2014","journal-title":"Skeletal Radiol."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108145_bb0025","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13023-017-0733-y","article-title":"Failure to shorten the diagnostic delay in two ultra-orphan diseases (mucopolysaccharidosis types I and III): potential causes and implications","volume":"13","author":"Kuiper","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"issue":"6","key":"10.1016\/j.ymgme.2024.108145_bb0030","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/jmedgenet-2015-103322","article-title":"Clinical course of sly syndrome (mucopolysaccharidosis type VII)","volume":"53","author":"Monta\u00f1o","year":"2016","journal-title":"J. Med. Genet."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108145_bb0035","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s13023-021-01870-w","article-title":"Mucopolysaccharidosis VII in Brazil: natural history and clinical findings","volume":"16","author":"Giugliani","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"issue":"3","key":"10.1016\/j.ymgme.2024.108145_bb0040","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ymgme.2017.05.016","article-title":"Epidemiology of mucopolysaccharidoses","volume":"121","author":"Khan","year":"2017","journal-title":"Mol. Genet. Metab."},{"issue":"4","key":"10.1016\/j.ymgme.2024.108145_bb0045","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/humu.20828","article-title":"Mutations and polymorphisms in GUSB gene in mucopolysaccharidosis VII (Sly syndrome)","volume":"30","author":"Tomatsu","year":"2009","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymgme.2024.108145_bb0050","series-title":"GUSB glucuronidase beta [Homo sapiens (human)]","author":"Gene [Internet]","year":"2004"},{"key":"10.1016\/j.ymgme.2024.108145_bb0055","unstructured":"S. Daughtery, T. Hamazaki, M. Hegde, et al. Mucopolysaccaridiosis type VII (MPS VII): GUSB gene variant database. Presented at American Society of Human Genetics, November 1-5 (2023), Washington D.C., USA."},{"issue":"3","key":"10.1016\/j.ymgme.2024.108145_bb0060","first-page":"517","article-title":"Mutational analysis of a patient with mucopolysaccharidosis type VII, and identification of pseudogenes","volume":"52","author":"Shipley","year":"1993","journal-title":"Am. J. Hum. Genet."},{"issue":"4","key":"10.1016\/j.ymgme.2024.108145_bb0065","first-page":"798","article-title":"Pseudodeficiency allele (D152N) of the human beta-glucuronidase gene","volume":"57","author":"Vervoort","year":"1995","journal-title":"Am. J. Hum. Genet."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108145_bb0070","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ccr3.3644","article-title":"Prenatal mucopolysaccharidosis VII: a novel pathogenic variant identified in GUSB gene","volume":"9","author":"Poyatos-And\u00fajar","year":"2021","journal-title":"Clin. Case Rep."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108145_bb0075","first-page":"89","article-title":"Mucopolysaccharidosis type VII: characterization of mutations and molecular heterogeneity","volume":"48","author":"Tomatsu","year":"1991","journal-title":"Am. J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108145_bb0080","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s004390050656","article-title":"Low beta-glucuronidase enzyme activity and mutations in the human beta-glucuronidase gene in mild mucopolysaccharidosis type VII, pseudodeficiency and a heterozygote","volume":"102","author":"Vervoort","year":"1998","journal-title":"Hum. Genet."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108145_bb0085","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1186\/s13023-021-02063-1","article-title":"Description of the molecular and clinical characteristics of the mucopolysaccharidosis type VII Iberian cohort","volume":"16","author":"G\u00f3nzalez-Meneses","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108145_bb0090","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s40259-019-00344-7","article-title":"Vestronidase alfa: a review in Mucopolysaccharidosis VII","volume":"33","author":"EH","year":"2019","journal-title":"BioDrugs"},{"issue":"9","key":"10.1016\/j.ymgme.2024.108145_bb0095","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/gim.2017.10","article-title":"Quantitative clinical characteristics of 53 patients with MPS VII: a cross-sectional analysis","volume":"19","author":"Zielonka","year":"2017","journal-title":"Genet. Med."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108145_bb0100","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s13023-019-1233-z","article-title":"Pathway to diagnosis and burden of illness in mucopolysaccharidosis type VII - a European caregiver survey","volume":"14","author":"Morrison","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108145_bb0105","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ajog.2014.12.018","article-title":"Society for maternal-fetal medicine (SMFM) clinical guideline #7: nonimmune hydrops fetalis","volume":"212","author":"Norton","year":"2015","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"12","key":"10.1016\/j.ymgme.2024.108145_bb0110","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1111\/apa.15260","article-title":"Non-immune hydrops fetalis was rare in Sweden during 1997-2015, but cases were associated with complications and poor prognosis","volume":"109","author":"Whybra","year":"2020","journal-title":"Acta Paediatr."},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2024.108145_bb0115","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/S1096-7192(21)00197-9","article-title":"Significant unmet need in infants with Mucopolysaccharidosis VII and Non-Immune Hydrops Fetalis: a summary of cases (eP112). 2021 Annual Clinical Genetics Meeting","volume":"132","author":"Marsden","year":"2021","journal-title":"Mol Genet Metab."},{"issue":"3","key":"10.1016\/j.ymgme.2024.108145_bb0120","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/uog.20371","article-title":"Association between mucopolysaccharidosis type VII and hydrops fetalis","volume":"55","author":"Holtz","year":"2020","journal-title":"Ultrasound Obstet. Gynecol."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108145_bb0125","first-page":"101","article-title":"Non-progressive nonimmune hydrops fetalis caused by a novel mutation in GUSB gene","volume":"14","author":"Mosallanejad","year":"2020","journal-title":"Iran J. Child Neurol."},{"issue":"6","key":"10.1016\/j.ymgme.2024.108145_bb0130","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/pd.5678","article-title":"Lysosomal storage disease spectrum in nonimmune hydrops fetalis: a retrospective case control study","volume":"40","author":"Al-Kouatly","year":"2020","journal-title":"Pren. Diagn."},{"issue":"18","key":"10.1016\/j.ymgme.2024.108145_bb0135","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1056\/NEJMoa2023643","article-title":"Exome sequencing for prenatal diagnosis in nonimmune hydrops fetalis","volume":"383","author":"Sparks","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2024.108145_bb0140","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1750-1172-7-86","article-title":"Lysosomal storage disorder in non-immunological hydrops fetalis (NIHF): more common than assumed? Report of four cases with transient NIHF and a review of the literature","volume":"7","author":"Whybra","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108145_bb0145","first-page":"1","article-title":"A rare late progression form of Sly syndrome mucopolysaccharidosis","volume":"49","author":"Guffon","year":"2019","journal-title":"JIMD Rep."},{"issue":"4","key":"10.1016\/j.ymgme.2024.108145_bb0150","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00431-019-03330-x","article-title":"Growth impairment and limited range of joint motion in children should raise suspicion of an attenuated form of mucopolysaccharidosis: expert opinion","volume":"178","author":"Guffon","year":"2019","journal-title":"Eur. J. Pediatr."},{"issue":"3","key":"10.1016\/j.ymgme.2024.108145_bb0155","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3390\/diagnostics10030172","article-title":"Diagnosis of mucopolysaccharidoses","volume":"10","author":"Kubaski","year":"2020","journal-title":"Diagnostics"},{"issue":"1\u20132","key":"10.1016\/j.ymgme.2024.108145_bb0160","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ymgme.2018.01.003","article-title":"Clinical presentation and diagnosis of mucopolysaccharidoses","volume":"125","author":"Stapleton","year":"2018","journal-title":"Mol. Genet. Metab."},{"issue":"4\u20135","key":"10.1016\/j.ymgme.2024.108145_bb0165","first-page":"413","article-title":"Unusually mild course of beta-glucuronidase deficiency in two brothers (mucopolysaccharidosis VII)","volume":"33","author":"Gitzelmann","year":"1978","journal-title":"Helv. Paediatr. Acta"},{"issue":"3","key":"10.1016\/j.ymgme.2024.108145_bb0170","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1136\/jmg.18.3.237","article-title":"Presentation of mucopolysaccharidosis VII (beta-glucuronidase deficiency) in infancy","volume":"18","author":"Hoyme","year":"1981","journal-title":"J. Med. Genet."},{"issue":"36","key":"10.1016\/j.ymgme.2024.108145_bb0175","article-title":"Growth patterns in patients with mucopolysaccharidosis VII","volume":"26","author":"Monta\u00f1o","year":"2023","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108145_bb0180","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ymgme.2014.10.017","article-title":"First human treatment with investigational rhGUS enzyme replacement therapy in an advanced stage MPS VII patient","volume":"114","author":"Fox","year":"2015","journal-title":"Mol. Genet. Metab."},{"issue":"6","key":"10.1016\/j.ymgme.2024.108145_bb0185","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/sj.bmt.1701141","article-title":"Treatment of MPS VII (Sly disease) by allogeneic BMT in a female with homozygous A619V mutation","volume":"21","author":"Yamada","year":"1998","journal-title":"Bone Marrow Transplant."},{"issue":"2\u20133","key":"10.1016\/j.ymgme.2024.108145_bb0190","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1089\/rej.2009.0920","article-title":"New strategies for enzyme replacement therapy for lysosomal storage diseases","volume":"13","author":"Grubb","year":"2010","journal-title":"Rejuvenation Res."},{"issue":"7","key":"10.1016\/j.ymgme.2024.108145_bb0195","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1016\/j.bbmt.2019.02.012","article-title":"Hematopoietic stem cell transplantation for mucopolysaccharidoses: past, present, and future","volume":"25","author":"Taylor","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"Suppl. 2","key":"10.1016\/j.ymgme.2024.108145_bb0200","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13052-018-0566-x","article-title":"A new case report of severe mucopolysaccharidosis type VII: diagnosis, treatment with haematopoietic cell transplantation and prenatal diagnosis in a second pregnancy","volume":"44","author":"Furlan","year":"2018","journal-title":"Ital. J. Pediatr."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108145_bb0205","article-title":"Long-term tollow-up posthematopoietic stem cell transplantation in a Japanese patient with type-VII mucopolysaccharidosis","volume":"10","author":"Orii","year":"2020","journal-title":"Diagnostics (Basel)."},{"issue":"21","key":"10.1016\/j.ymgme.2024.108145_bb0210","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20215345","article-title":"First report of a patient with MPS type VII, due to novel mutations in GUSB, who underwent enzyme replacement and then hematopoietic stem cell transplantation","volume":"20","author":"Dubot","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.ymgme.2024.108145_bb0215","doi-asserted-by":"crossref","DOI":"10.1111\/petr.13278","article-title":"Haematopoietic stem cell transplantation for mucopolysaccharidosis type VII: a case report","volume":"22","author":"Sisinni","year":"2018","journal-title":"Pediatr. Transplantation."},{"key":"10.1016\/j.ymgme.2024.108145_bb0220","series-title":"Mepsevii (vestronidase alfa) [product information]","author":"European Medicines Agency","year":"2020"},{"key":"10.1016\/j.ymgme.2024.108145_bb0225","series-title":"Mepsevii (vestronidase alfa)","year":"2020"},{"issue":"3","key":"10.1016\/j.ymgme.2024.108145_bb0230","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ymgme.2020.01.003","article-title":"The long-term safety and efficacy of vestronidase alfa, rhGUS enzyme replacement therapy, in subjects with mucopolysaccharidosis VII","volume":"129","author":"Wang","year":"2020","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108145_bb0235","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ymgme.2020.02.009","article-title":"Vestronidase alfa: recombinant human \u03b2-glucuronidase as an enzyme replacement therapy for MPS VII","volume":"130","author":"Cadaoas","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2024.108145_bb0240","article-title":"Open-label phase 1\/2 study of vestronidase alfa for mucopolysaccharidosis VII","volume":"28","author":"Jones","year":"2021","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"5","key":"10.1016\/j.ymgme.2024.108145_bb0245","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s40262-018-0721-y","article-title":"Pharmacokinetic and pharmacodynamic modeling to optimize the dose of vestronidase alfa, an enzyme replacement therapy for treatment of patients with mucopolysaccharidosis type VII: results from three trials","volume":"58","author":"Qi","year":"2019","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108145_bb0250","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ymgme.2022.03.002","article-title":"Long-term efficacy and safety of vestronidase alfa enzyme replacement therapy in pediatric subjects < 5 years with mucopolysaccharidosis VII","volume":"136","author":"Lau","year":"2022","journal-title":"Mol. Genet. Metab."},{"issue":"4","key":"10.1016\/j.ymgme.2024.108145_bb0255","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.ymgme.2018.02.006","article-title":"A novel blind start study design to investigate vestronidase alfa for mucopolysaccharidosis VII, an ultra-rare genetic disease","volume":"123","author":"Harmatz","year":"2018","journal-title":"Mol. Genet. Metab."},{"issue":"23","key":"10.1016\/j.ymgme.2024.108145_bb0260","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1056\/NEJMoa2200587","article-title":"In utero enzyme-replacement therapy for infantile-onset Pompe's disease","volume":"387","author":"Cohen","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ymgme.2024.108145_bb0265","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ymgme.2018.07.001","article-title":"Critical review of current MPS guidelines and management","volume":"126","author":"Stapleton","year":"2019","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108145_bb0270","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1542\/peds.2008-0416","article-title":"Management atICPot, I ToM, mucopolysaccharidosis I: management and treatment guidelines","volume":"123","author":"Muenzer","year":"2009","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.ymgme.2024.108145_bb0275","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00431-007-0635-4","article-title":"Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy","volume":"167","author":"Wraith","year":"2008","journal-title":"Eur. J. Pediatr."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108145_bb0280","article-title":"Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance","volume":"14","author":"Akyol","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108145_bb0285","article-title":"Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance","volume":"14","author":"Akyol","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108145_bb0290","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/j.ymgme.2020.12.141","article-title":"Disease characteristics, early effectiveness, and safety of vestronidase alfa for the treatment of mucopolysaccharidosis type VII (MPS VII) assessed in a novel, longitudinal, multicenter disease monitoring program (DMP)","volume":"132","author":"Lau","year":"2021","journal-title":"Mol. Genet. Metab."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719224000295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719224000295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T19:29:46Z","timestamp":1747337386000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719224000295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1096719224000295"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2024.108145","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mucopolysaccharidosis type VII (Sly syndrome) - What do we know?","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2024.108145","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108145"}}